EGFR and cancer: As a consequence, the treatment of Caski and CSCC1 cancer cells with the anti-EGFR antibody cetuximab resulted in a higher production of IFN-γ and TNF-α-induced cytokines than when the cancer cells were treated with the control anti-CD20 antibody rituximab (Fig. 5f; Supplementary Fig. 5c).